DRI Healthcare Trust (TSE:DHT.UN) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of DRI Healthcare Trust (TSE:DHT.UN) have been given an average recommendation of “Moderate Buy” by the six research firms that are presently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is C$17.94.

A number of equities analysts have commented on DHT.UN shares. CIBC reduced their price objective on DRI Healthcare Trust from C$19.50 to C$18.00 and set an “outperform” rating on the stock in a research note on Thursday, December 12th. Raymond James reduced their price target on shares of DRI Healthcare Trust from C$23.00 to C$22.00 in a research report on Wednesday, November 13th.

DRI Healthcare Trust Stock Performance

TSE DHT.UN opened at C$11.86 on Tuesday. The stock’s 50 day simple moving average is C$12.06 and its 200 day simple moving average is C$12.58. DRI Healthcare Trust has a one year low of C$10.39 and a one year high of C$17.43.

About DRI Healthcare Trust

DRI Healthcare Trust is an open-ended trust that provides unitholders with differentiated exposure to the anticipated growth in the global pharmaceuticals and biotechnology markets. Its business model is focused on managing and growing a diversified portfolio of pharmaceutical royalties to deliver attractive growth in cash royalty receipts over the long term.